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To the Editor:
The October 2014 issue (Vol. 9, 
no. 10) contained two articles about 
the management of “oligometastatic 
disease” which need comment. The 
first is a “concise review” of the role of 
stereotactic ablative radiotherapy in the 
management of pulmonary oligome-
tastases and oligometastatic disease.1 
A review published in a respected peer 
review journal should give some indica-
tion of how the evidence was identified, 
appraised, and used. In this case, there 
was no information on methods and it 
would appear that no systematic search 
was carried out as papers questioning 
the value of pulmonary metastasectomy 
were not cited. Although the issue of 
selection bias in the current literature, 
which is composed entirely of retrospec-
tive case series, was briefly discussed in 
the introduction, later when discussing 
“Future Trials and Conclusion,” selec-
tion bias was referred to as a “specter.” 
This implies that it is a ghostly illusion 
that needs exorcising, not a very real 
limitation to the available evidence.
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To the Editor:
Recently, we are interested to read 
the article by Tan et al.1 regarding the 
prognostic significance of lymph node 
ratio (LNR) in patients with esophageal 
cancer. The authors conclude that the 
LNR is an independent prognostic factor 
and prognosticates long-term outcomes 
of esophageal cancer after tri-incisional 
esophagectomy. We appreciated the 
authors on their excellent study, but we 
have some comments regarding their 
conclusions. First, we are puzzled about 
the authors’ conclusion that the number 
of LN metastasis is not an independent 
prognostic factor. Most of the studies2,3 
have shown that the number of LN metas-
tasis is an independent prognostic factor 
in esophageal cancer patients after esoph-
agectomy. We observed that the number 
of metastatic LNs was significantly cor-
related to that of retrieved LNs in the 
authors’ article. And our experience also 
suggests the number of metastatic LNs is 
closely related to the number of stations 
of metastatic LNs. If there is strong cor-
relation between variables in cox model, 
estimation of cox model parameters will 
be affected, and some variables affect-
ing prognosis will be excluded from the 
model for multi-collinearity.4 So principal 
components analysis or r-type clustering 
analysis should be used to eliminate the 
influence of multi-collinearity.4 However, 
authors’ inclusion of factors with close 
correlation in multivariate analysis, with-
out statistical adjustment, comes to con-
clusion that the number of LN metastasis 
is not an independent prognostic factor. 
Second, patients with the number of 
retrieved LNs less than 15 accounted for 
53.7% (376 of 700), which means LNs 
dissection in more than half of patients 
is insufficient. The authors’ results that 
higher LNR indicates poor prognosis can 
be explained that insufficient LNs dissec-
tion can miss occult metastatic LNs which 
lead to stage migration and overestimat-
ing the patients’ prognosis. Third, we find 
the numbers of patients with stage N2 and 
N3 are only 69 and 28, respectively, which 
makes few patients included in subgroup 
analysis. As Table 4 of the authors’ article 
shows, the number of patients with stage 
N2 and N3 in T1 and T2 subgroup is 
too small to achieve sufficient statistical 
power. We think it is not sufficient to draw 
the conclusion by authors that no signifi-
cant survival difference is observed in 
pN categories stratified by tumor status. 
Therefore, we should stick to the point 
that LNR is still not enough to replace 
the pN categories based on metastatic LN 
counts in the tumor-node metastasis clas-
sification system for esophageal cancer.
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In their Letter to the Editor, Drs. F. 
Macbeth and T. Treasure refer to two 
articles published in the October 2014 
issue of Journal of Thoracic Oncology 
related to treatment of lung metasta-
ses.1–3 They correctly point out that there 
are no large randomized trials to provide 
a definite proof that resection of lung 
metastases prolongs survival in patients. 
They even take it one step back and pro-
pose to obtain level I evidence before 
performing further studies. In this 
regard, they could have chosen many 
surgical papers that were recently pub-
lished in Journal of Thoracic Oncology. 
For most thoracic surgical procedures 
there is no such evidence to support 
them. This relates to surgery for medi-
astinal tumors as thymoma, mesotheli-
oma, locally advanced lung cancer, and 
even early stage lung cancer! Does this 
mean that surgery is not a valid treat-
ment, as the authors seem to suggest? 
How to approach individual patients 
when there is lack of level I evidence? 
Although not very clearly, the authors 
suggest that we should not continue 
any treatment modality until this evi-
dence becomes available. However, they 
have not proven the reverse statement: 
“absence of evidence” does not mean 
“evidence of absence” as indicated in 
several editorials.4 They state that “there 
is reason to believe that any perceived 
survival benefit may simply be because 
of patient selection.” This is not a very 
scientific statement and not a single ref-
erence is mentioned to support this.
Surgery became an accepted 
treatment for many tumors as it pro-
vides the opportunity to completely 
remove the primary tumor and drain-
ing lymph nodes although no formal 
comparison with conservative treat-
ment is available. For this reason, there 
is an inherent problem when proposing 
randomized trials comparing surgery 
to conservative management which 
is often perceived as treatment with-
drawal. Even when randomized trials 
are performed, there is still no absolute 
truth and a certain degree of uncer-
tainty remains.4 Moreover, the con-
clusions are only valid for the study 
population for which strict inclusion 
and exclusion criteria were designed. 
For rare tumors as mesotheliomas 
and thymomas it will never be pos-
sible to perform a large randomized 
Reply to “Pulmonary 
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Absence of Evidence 
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Secondly, there is a report of the 
use of whole lung perfusion after pul-
monary metastasectomy for colorectal 
cancer or sarcoma.2 This starts by saying 
that the prognosis of these patients has 
not changed in 20 years, but their conclu-
sion is not that perhaps metastasectomy 
does not make a difference, but seems 
to be “we need to do something more.” 
They report the use a toxic drug without 
a good track record in either tumor to 
perfuse the whole lung and that 44% of 
patients experienced grade 3 or 4 toxicity. 
Although there was an apparent reduction 
in pulmonary metastases there seemed to 
be no improvement in time to progres-
sion or overall survival—compared with 
historical series.
There is an increasingly embedded 
view that pulmonary metastasectomy is 
a proven and effective surgical treatment 
that improves patient outcomes and so 
now people are investigating less inva-
sive techniques (e.g., stereotactic abla-
tive radiotherapy and radiofrequency 
ablation) or, adding locally perfused 
chemotherapy. Both papers cite the 1997 
publication of International Registry on 
Lung Metastasis3 which was a landmark 
in pooling uncontrolled data, permitting 
analysis of over 5000 cases. But it contains 
no evidence on what might have been the 
survival among similarly selected patients 
without metastasectomy—there were no 
controls and that remains the case.4
Not only are the patients having 
metastasectomy highly selected but so 
too are citations in the publication.5 
Pulmonary metastasectomy is a good 
example of how selective citation and 
repeated authoritative publication can 
create “facts” from hypotheses. There is 
no randomized trial evidence to support 
the belief that it is an effective inter-
vention and there is reason to believe 
that any perceived survival benefit may 
simply be because of patient selection. 
This is an insecure foundation of which 
to justify ablative therapies.6 Before 
embarking on more, uncontrolled 
research into “better” ways of remov-
ing pulmonary metastases, there need 
to be well-conducted randomized trials 
investigating the value of the procedure.
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